A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin in Chronic Hepatitis C Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-02.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing paritaprevir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. paritaprevir · Hepatitis C.
Among the 29 studies testing paritaprevir in Hepatitis C, this one is the 3rd largest by enrollment, is one of 6 that started in 2012, is one of 14 in phase 3, and was the 13th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 29 studies testing paritaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 99 across the 29 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 6 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
90 studies in Hepatitis C by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 88 finished, 71 (81%) have results posted.
Among the 90 studies in Hepatitis C by AbbVie, this one is the 12th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2012, is one of 46 in phase 3, and was the 17th registered.
AbbVie’s Hepatitis C studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing paritaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 90 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected treatment-experienced adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin
Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin · Drug: Placebo for ABT-450/r/ABT-267 · Drug: Placebo for ABT-333 · Drug: Placebo for ribavirin
Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir
Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK
Capsule (double-blind treatment period), tablet (open-label treatment period)
Tablet
Tablet
Capsule
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of active study drug
Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.
Time frame: At 12 weeks
Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of active study drug
Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of active study drug
Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid \[HCV RNA\] ≥ lower limit of quantification \[LLOQ\] after HCV RNA \< LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.
Time frame: 12 weeks after the last actual dose of active study drug
Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
Time frame: Within 12 weeks post-treatment
| Milestone | ABT-450/r/ABT-267 and ABT-333, Plus RBV | Placebo Followed by ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|---|
| Started | 297 | 98 |
| Randomized but not treated | 0 | 1 |
| Completed | 292 | 96 |
| Not completed | 5 | 2 |
| Withdrew: Did not receive study drug | 0 | 1 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Other | 1 | 0 |
| Milestone | ABT-450/r/ABT-267 and ABT-333, Plus RBV | Placebo Followed by ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|---|
| Started | 0 | 96 |
| Completed | 0 | 94 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Subject noncompliant | 0 | 1 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment | 96.3 |
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV | Placebo |
|---|---|---|
| Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period | 96.9 | 12.8 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|
| Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment | 96.0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|
| Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment | 96.7 |
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid \[HCV RNA\] ≥ lower limit of quantification \[LLOQ\] after HCV RNA \< LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|
| Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm | 0 (0.0 to 0.0) |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
| percentage of participants | ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|
| Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm | 2.4 (0.6 to 4.1) |
Collected over Adverse events (AEs) were collected from the start of active study drug administration (double-blind [DB] or open-label [OL] active) to 30 days after the last dose of active study drug (total 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind ABT-450/r/ABT-267 and ABT-333, Plus RBV | — | 6/297 (2%) | 254/297 (85.5%) |
| Double Blind Placebo | — | 1/97 (1%) | 74/97 (76.3%) |
| Open Label ABT-450/r/ABT-267 and ABT-333, Plus RBV | — | 3/96 (3.1%) | 74/96 (77.1%) |
| Event | Double Blind ABT-450/r/ABT-267 and ABT-333, Plus RBV | Double Blind Placebo | Open Label ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|---|---|
| BILE DUCT STONEHepatobiliary disorders | 0/297 | 0/97 | 1/96 |
| CALCULUS URETERICRenal and urinary disorders | 0/297 | 0/97 | 1/96 |
| ANGIOEDEMASkin and subcutaneous tissue disorders | 0/297 | 0/97 | 1/96 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/297 | 1/97 | 0/96 |
| BRADYCARDIACardiac disorders | 1/297 | 0/97 | 0/96 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/297 | 0/97 | 0/96 |
| NAUSEAGastrointestinal disorders | 1/297 | 0/97 | 0/96 |
| VOMITINGGastrointestinal disorders | 1/297 | 0/97 | 0/96 |
| PNEUMONIAInfections and infestations | 1/297 | 0/97 | 0/96 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 1/297 | 0/97 | 0/96 |
| Event | Double Blind ABT-450/r/ABT-267 and ABT-333, Plus RBV | Double Blind Placebo | Open Label ABT-450/r/ABT-267 and ABT-333, Plus RBV |
|---|---|---|---|
| HEADACHENervous system disorders | 108/297 | 34/97 | 18/96 |
| FATIGUEGeneral disorders | 99/297 | 22/97 | 16/96 |
| NAUSEAGastrointestinal disorders | 59/297 | 17/97 | 13/96 |
| ASTHENIAGeneral disorders | 47/297 | 11/97 | 13/96 |
| INSOMNIAPsychiatric disorders | 42/297 | 7/97 | 10/96 |
| PRURITUSSkin and subcutaneous tissue disorders | 41/297 | 5/97 | 12/96 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 37/297 | 10/97 | 13/96 |
| DIARRHOEAGastrointestinal disorders | 39/297 | 12/97 | 8/96 |
| COUGHRespiratory, thoracic and mediastinal disorders | 32/297 | 5/97 | 11/96 |
| MYALGIAMusculoskeletal and connective tissue disorders | 23/297 | 10/97 | 5/96 |
Safety population: all randomized participants who received at least 1 dose of blinded study drug.
| Age, Continuous(years) | ABT-450/r/ABT-267 and ABT-333, Plus RBV | Placebo | Total |
|---|---|---|---|
| Mean | 51.7 ± 10.26 | 54.9 ± 8.46 | 52.5 ± 9.93 |
| Sex: Female, Male(Participants) | ABT-450/r/ABT-267 and ABT-333, Plus RBV | Placebo | Total |
|---|---|---|---|
| Female | 130 | 37 | 167 |
| Male | 167 | 60 | 227 |
No study locations are listed for this record.
The record gives a start of Nov 2012, a primary completion of Nov 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin
AbbVie (prior sponsor, Abbott) →